PepGen (NASDAQ:PEPG) Issues Quarterly Earnings Results

PepGen (NASDAQ:PEPG) released its quarterly earnings results on Monday. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.13, Zacks reports.

PepGen Price Performance

NASDAQ PEPG opened at $2.29 on Tuesday. The company’s fifty day moving average is $2.51 and its two-hundred day moving average is $5.83. PepGen has a 52-week low of $1.16 and a 52-week high of $19.30. The firm has a market capitalization of $74.65 million, a price-to-earnings ratio of -0.77 and a beta of 1.53.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Bank of America downgraded shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a report on Monday, December 16th. Wedbush dropped their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of PepGen in a research note on Monday.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.